| Literature DB >> 29207339 |
Michael Saleeb1, Charlotta Sundin1, Öznur Aglar1, Ana Filipa Pinto2, Mahsa Ebrahimi2, Åke Forsberg3, Herwig Schüler2, Mikael Elofsson4.
Abstract
During infection, the Gram-negative opportunistic pathogen Pseudomonas aeruginosa employs its type III secretion system to translocate the toxin exoenzyme S (ExoS) into the eukaryotic host cell cytoplasm. ExoS is an essential in vivo virulence factor that enables P. aeruginosa to avoid phagocytosis and eventually kill the host cell. ExoS elicits its pathogenicity mainly via ADP-ribosyltransferase (ADPRT) activity. We recently identified a new class of ExoS ADPRT inhibitors with in vitro IC50 of around 20 μM in an enzymatic assay using a recombinant ExoS ADPRT domain. Herein, we report structure-activity relationships of this compound class by comparing a total of 51 compounds based on a thieno [2,3-d]pyrimidin-4(3H)-one and 4-oxo-3,4-dihydroquinazoline scaffolds. Improved inhibitors with in vitro IC50 values of 6 μM were identified. Importantly, we demonstrated that the most potent inhibitors block ADPRT activity of native full-length ExoS secreted by viable P. aeruginosa with an IC50 value of 1.3 μM in an enzymatic assay. This compound class holds promise as starting point for development of novel antibacterial agents.Entities:
Keywords: 2-Aminobenzamide; ADP-Ribosyltransferase; Bacterial exotoxins; ExoS; Pseudomonas aeruginosa; Quinazolines; Type III secretion
Mesh:
Substances:
Year: 2017 PMID: 29207339 DOI: 10.1016/j.ejmech.2017.11.036
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514